GlassScriptPhysician profile
Wegdan Andrews
NPI 1972511723
$6,407.09
in general payments reported to CMS, 2019-2025
39 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2022: $690 · 2023: $1,725 · 2024: $2,038 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,590.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,290.84 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $793.92 | 2023-2025 | |
| Abbott Laboratories | $216.26 | 2022-2025 | Infinity, Proclaim |
| Teva Pharmaceuticals USA, INC. | $206.90 | 2022-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $194.84 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $163.83 | 2019-2025 | |
| Lilly USA, LLC | $125.45 | 2024-2025 | Kisunla, Amyvid |
| Lundbeck LLC | $114.29 | 2023-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $91.18 | 2023-2024 | Valtoco |
| Amneal Pharmaceuticals LLC | $91.13 | 2022-2025 | Rytary, Crexont |
| Amgen INC. | $81.90 | 2022-2024 | Uplizna, Aimovig |
| Biogen, INC. | $81.57 | 2023-2025 | Spinraza, Skyclarys, Vumerity |
| Eisai INC. | $80.69 | 2022-2023 | |
| Grifols USA, LLC | $79.11 | 2022-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $65.56 | 2025 | Hyqvia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wegdan Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.